Pharmidex joins London Mayor Boris Johnson's trade mission to US
January 6, 2015

Boris Johnson is heading to the United States on a six-day trade mission aimed at bolstering London's science and technology industries.

Mr Boris Johnson’s US Trade Mission


Mr Boris Johnson, the Mayor of London has recently been in the US trying to attract investment for British businesses. Mr Johnson is using the US trade mission to promote London's TechCity - which supports the cluster of technology firms based in east London - and MedCity, which was launched last year to support life sciences.


He looked to visit Harvard University’s Stem Cell Institute (HSCI) in an attempt to bring together collaborations between London and Boston life sciences. Mr Johnson said “'The United States is a hugely important trading partner for London, offering massive opportunities for investment in this country and for businesses wanting to expand internationally. I want London to capitalise on the great relationships we have in Boston, New York City and Washington DC”.


In Boston and New York, the Mayor was joined by senior business figures from London's tech and life science sectors including Dr Mo Alavijeh of Pharmidex.


For more information please see: http://www.bbc.co.uk/news/uk-england-london-31161270

World Asthma Day 🌍

May 5, 2026
Asthma affects over 260 million people worldwide and remains a significant unmet medical need. At Pharmidex , we are proud to support the development of next-generation respiratory therapies through: In vivo respiratory disease models Whole Body Plethysmography (WBP) for functional readouts Integrated PK/PD and bioanalysis Our focus is simple: generate high-quality data that enables confident decision-making and accelerates progress for patients. Because behind every dataset is a patient waiting to breathe easier.

Funding Opportunity for Early-Stage Innovators in Scotland

May 1, 2026
Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment. 🗓️ Deadline: 8th May At Pharmidex , we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development. Our capabilities include: TargetExpression ModeOfActionStudies TargetEngagement HitIdentification ADME and PK profiling If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme. 🔗 https://lnkd.in/eZ6vVjgN

We’re pleased to introduce the Pharmidex Senior Management Team

April 29, 2026
We’re pleased to introduce the Pharmidex Senior Management Team (SMT), bringing together expertise across drug discovery, bioanalysis, DMPK, and translational science: 🔹 Alix Hampson 🔹 Dr Mansoor Chishty 🔹 Prof Mo Alavijeh (FRSC, FRSM) 🔹 Dr Martin Barrett 🔹 Dr Stephen Mitchell 🔹 Ash Alavijeh Collectively, the team brings 150+ years of combined experience, supporting programmes from discovery through to the clinic and beyond. We’ve also seen firsthand how similar pieces, in the hands of our 400+ innovative clients, can be combined to unlock real impact for patients. To mark the occasion, we’ve reimagined our SMT in LEGO style 🧱 Much like LEGO: • Great things are built step by step • Every piece has a purpose • The best outcomes come from creativity, collaboration, and continuous evolution At Pharmidex, it’s about bringing the right pieces together, to build smarter solutions and better outcomes.
More Posts